

Concept Development Form

Please ensure that your concept addresses the majority of points noted in the Concept Development Form below. A checklist is provided below to aid investigators in preparing their concept for submission to ANZGOG.

Concepts are reviewed by the Research Advisory Committee, consumers and our collaborative partners, NHMRC CTC.

Email to: concepts@anzgog.org.au Date of submission: **Concept Title** Study Phase ☐ Phase I ☐ Phase II ☐ Phase III ☐ Other □ Ovarian □ Cervical □ Endometrial □ Other **Cancer Type Background and Significance Study Summary** Aims: Hypothesis: Objectives: **Endpoints: Subject Population Study Procedures Statistical Considerations** Feasibility Biospecimen Collection /Translational Research **Quality of Life Assessment Health Economics Funding** ☐ Budget developed ☐ Funded ☐ Pending ☐ None Funding options for consideration: ☐ NHMRC/CA ☐ Local Institution ☐ ANZGOG ☐ Other



Drugs and sponsorship

Pharma Co:

Drug:

	Will pharma provide drug? Yes □ No □ N/A □
	Pharma contact information:
Lay summary for consumer review (250 words)	
List of other collaborative trial groups involved	
Protocol	In development: ☐ Yes ☐ No
	Assistance required from ANZGOG to develop further: ☐ Yes ☐ No
ANZGOG involvement requested	Multi-centre trial with ANZGOG Study Identification:
	☐ coordinated by the ANZGOG/CTC Collaboration
	□ coordinated by another centre
	☐Other research study seeking ANZGOG Study Identification:
	Describe
	☐ limited or single centre study
	☐ Unknown, to be determined
Study Chair Name:	Organisation:
Speciality:	Email:
Phone:	Mobile:
Thoric.	Woolie.
Investigator/s	
	d in the surname-last format with the initial in capital. Institutional perscript numbers following the author name. n, city and country.
Example:	
J Smith ¹ , S Doe ¹ ¹ Department of Oncology, XYZ Hospita	l, Sydney, Australia
Investigator/s (list all)	

Affiliations (list all the institutions)	l
,	
	l
	l
	l
	l
\mathbf{i}	1

Guidelines for completing your concept

CONCEPT TITLE

Should be in the PICO format (ie the title should hold information on the Participants, Intervention and Comparison groups, and the Outcomes of the trial).

BACKGROUND AND SIGNIFICANCE

- Have you addressed the scientific validity?
- Is it an important question?
- Size of population defined?
- Sufficient rationale to proceed?
- Is it clinically relevant?
- Have you searched ANZCTR and other registries? www.anzctr.org.au

STUDY SUMMARY

- Aims:
 - i. Are they clearly stated?
- Trial objectives
 - ii. Do they match aims?
- Hypotheses:
 - iii. Are they clearly stated?
 - iv. Do they match aims and objectives?
- Endpoints:
 - i. Are they measurable?
 - ii. Are they suitable to answer trial questions?

STUDY DESIGN AND STATISTICS

- Phase of study?
- Is design appropriate to address the question?
- Are treatment arms clearly described?
- What is the sample size estimate?
- Is the sample size justified in terms of primary endpoint?
- Is the study likely to detect a clinically significant difference?
- Has a statistician reviewed the study design?
- Is the study feasible? Outline the proposed sources of subjects and estimated recruitment rates.

SUBJECT POPULATION

 Target population and setting should be described briefly. Main inclusion criteria – are they clearly stated and clinically relevant?

STUDY INTERVENTION

Briefly describe actions to be taken

FUNDING

– Is there any financial support for the study?

OTHER

- Is there a translational research component?
- Have QOL and Health Economics assessments been included?
- Is there collaborative support from other trials groups